Lyka Labs Limited successfully held its 47th Annual General Meeting (AGM) on Monday, 10th August 2026, at 12:30 P.M. through Video Conference/Other Audio-Visual Means (VC/OAVM). All five resolutions placed before the shareholders were passed with the requisite majority via remote e-voting and e-voting during the meeting. The scrutinizing process was conducted by Kaushal Doshi, Practicing Company Secretary and Proprietor of M/s. Kaushal Doshi & Associates, appointed by the Board of Directors vide resolution dated 25th May 2026.

Meeting Participation and Voting Overview

The record date for determining eligible shareholders was 3rd August 2026, with a total of 29,814 shareholders on record. Attendance at the meeting was entirely through video conferencing, with no shareholders present in person or through proxy. The following table summarises meeting attendance:

The remote e-voting period commenced on Thursday, 6th August 2026 at 09:00 A.M. and ended on Sunday, 9th August 2026 at 5:00 P.M. NSDL was appointed as the service provider for the e-voting facility.

Summary of Resolutions and Voting Results

All five resolutions were ordinary resolutions. The voting results, as certified by the Scrutinizer, are summarised below:

Interested Directors, their relatives, and other related parties abstained from voting.

Resolution-wise Voting Details

For Resolutions 1, 2, 3, and 4, the total votes polled across all categories stood at over 22 million, reflecting strong participation primarily from the Promoter and Promoter Group category. The detailed category-wise breakdown for Resolution 1 is as follows:

For Resolution 5, concerning approval of material related party transactions with IPCA Laboratories Limited for FY 2026-27, the Promoter and Promoter Group abstained from voting as interested parties. As a result, the total votes polled for this resolution stood at 1036306, representing 2.8665% of outstanding shares, with 1034655 votes (99.8407%) cast in favour and 1651 votes (0.1593%) against.

Key Resolutions at a Glance

The five resolutions passed at the 47th AGM covered the following key matters:

• Adoption of Financial Statements: Both standalone and consolidated audited financial statements for the financial year ended 31st March 2026, along with the Reports of the Board of Directors and Auditors, were adopted.
• Director Re-appointment: Mr. Shashil Philip Mendonsa (DIN: 09667654), who retired by rotation, was re-appointed as Director.
• Cost Auditor Remuneration – FY 2025-2026: Ratification of the remuneration of the Cost Auditor for FY 2025-2026 was approved.
• Cost Auditor Remuneration – FY 2026-2027: Ratification of the remuneration of the Cost Auditor for FY 2026-2027 was approved.
• Related Party Transactions: Approval of material related party transactions with IPCA Laboratories Limited for the Financial Year 2026-27 was granted, with interested directors, their relatives, and other related parties abstaining from voting.

The Scrutinizer's Report was issued on 10th August 2026 and the consolidated e-voting results were submitted to the stock exchanges in compliance with Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company Secretary and Compliance Officer, Shailendra Agrawal, confirmed that all resolutions were carried with the requisite majority.

Lyka Labs Limited submitted revised unaudited financial results for the first quarter of FY27 on August 11, 2026, correcting minor typographical errors in its earlier filing. The revision primarily adjusted the standalone net profit after tax to ₹210.03 lakh, up from the previously reported ₹210.01 lakh, representing a 159.06% year-on-year increase. Consolidated net profit remained unchanged at ₹204.66 lakh, marking a 105.44% jump. The strong profitability turnaround was driven by a robust 68.03% surge in export revenues, which reached ₹1,483.42 lakh, offsetting a decline in other income and rising finance costs.

The Board of Directors approved the unaudited financial results on August 10, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed the stock exchanges that the revised press release corrects specific financial figures while all other data remains unchanged. Statutory auditors have provided an unqualified conclusion on the financial statements for the quarter ended June 30, 2026.

Financial Performance

Lyka Labs’ standalone revenue from operations grew 45.01% to ₹4,230.94 lakh in Q1FY27, compared to ₹2,917.64 lakh in the corresponding period last year. Consolidated revenue expanded 28.11% to ₹4,230.94 lakh from ₹3,302.54 lakh. While top-line growth was robust, EBITDA margins contracted slightly due to higher finance costs and lower other income.

Standalone EBITDA increased 21.32% to ₹501.14 lakh, but the margin compressed to 11.84% from 14.16% in Q1FY26. Consolidated EBITDA rose 15.02% to ₹496.57 lakh, with margins slipping to 11.74% from 13.07%. Finance costs increased 18.42% to ₹100.82 lakh (standalone), while other income declined 45.89% to ₹41.85 lakh.

Revenue Breakdown

The revenue mix showed distinct trends between domestic and international markets. Export revenues surged 68.03% to ₹1,483.42 lakh, entirely driven by branded formulations. In contrast, domestic sales grew at a more modest 15.91% to ₹2,652.11 lakh. Within the domestic segment, branded veterinary products nearly doubled, up 97.83% to ₹587.35 lakh, while branded human formulations rose 62.27% to ₹737.67 lakh. However, Principal-to-Principal (P2P) sales declined 13.64% to ₹1,327.09 lakh.

What the Numbers Show

The disproportionate growth in exports versus domestic sales highlights Lyka Labs’ increasing reliance on international markets for top-line expansion. While the 159% jump in net profit is impressive, it is partly aided by base effects from Q1FY26. The contraction in EBITDA margins despite high revenue growth suggests that input costs or pricing pressures in the export segment may be intensifying. Additionally, the decline in P2P sales warrants monitoring, as it could impact volume stability if not offset by continued strength in branded formulations.